Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant

摘要

Purpose Fosaprepitant (Emend (R)) is an antiemetic frequently used for the prevention of chemotherapy-induced nausea and vomiting. We previously documented an overall 28.7% incidence of infusion-site reactions in patients receiving fosaprepitant via peripheral venous access. These data resulted in a practice change within our institution; fosaprepitant is administered in more dilute concentrations over 30min to prevent these adverse events. This retrospective study explored the impact of this practice change on the incidence of infusion-site reactions.